Evidence map›Paper›PMID 32228630›Full record

ArticleHealth and quality of life outcomes2020

Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study.

Janice Andersen, Janne Thomsen, Åshild Rostad Enes, Sverre Sandberg, Aasne K Aarsand

Open access · goldAbstract read
In one paragraph

Article in Health and quality of life outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. German Porphyria Registry (PoReGer)-Background and Setup.Healthcare (Basel, Switzerland) · 2024
    Article
  4. Article
  5. Article
  6. Reducing research wastage by starting off on the right foot: optimally framing the research question.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Janice AndersenDepartment of Medical Biochemistry and Pharmacology, Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital, N-5021, Bergen, Norway. janice.andersen@helse-bergen.no.ORCID https://orcid.org/0000-0003-3028-9215
Janne ThomsenDepartment of Medical Biochemistry and Pharmacology, Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital, N-5021, Bergen, Norway.
Åshild Rostad EnesDepartment of Medical Biochemistry and Pharmacology, Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital, N-5021, Bergen, Norway.
Sverre SandbergDepartment of Medical Biochemistry and Pharmacology, Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital, N-5021, Bergen, Norway.
Aasne K AarsandDepartment of Medical Biochemistry and Pharmacology, Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital, N-5021, Bergen, Norway.
Haukeland University Hospital · NO

Funding

Norwegian National Advisory Unit on Rare Disorders Not applicable
6 · The paper itself

Abstract

backgroundPorphyria cutanea tarda (PCT) is a rare, photosensitive disease characterized by skin fragility and blistering on sun-exposed areas. There is little previous research on how this condition affects health-related quality of life (HRQoL) and to the best of our knowledge this is the largest sample of PCT patients surveyed about their HRQoL. The aims of this study were to describe HRQoL, symptoms, susceptibility factors, disease activity and treatment in patients with PCT, and investigate the associations between these factors.

methodsThis is a cross-sectional, retrospective study based on patient-reported outcome and laboratory data. The Norwegian Porphyria Centre diagnoses all patients with PCT in Norway, all of whom are invited to participate in the Norwegian Porphyria Registry. Between December 2013-2015, 111 patients received a postal questionnaire and invitation to participate.

resultsSixty-eight persons responded, with seven being excluded due to prolonged response time or missing information, resulting in 61 participants in the final analyses (55%). Median age was 60 years and 33 were female. We found a moderate negative relationship between the type and localisation of PCT symptoms and both mental (r = -.354 p < 0.01) and physical (r = -.441, p < 0.01) aspects of HRQoL. Participants who had started treatment when answering the questionnaire reported significantly better physical functioning and less bodily pain than those who had not started treatment. We did not observe an association between biochemical markers of disease activity and symptoms or HRQoL. Itching, a symptom that has received little attention in PCT was reported by 59% of the participants.

conclusionsOur results show that reduced HRQoL is associated with more symptoms and not having started treatment. PCT is a rare disease, and there is a need for the development of best-practice guidelines to facilitate good patient care.

Indexed as

Quality of LifeAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedNorwayPorphyria Cutanea TardaRegistriesRetrospective StudiesSurveys and QuestionnairesHRQoLPhotodermatosisPorphyriaPorphyria cutanea tardaQuality of lifeRegistrySF-12

Identifiers

PMID32228630
PMCPMC7106654
OpenAlexW3013899088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.